A cell culture/biotech company making strides in enhancing organ preservation and cell culturing at both room temperature and through cryopreservation. The LIFOR® technology is the nanoparticle component of the solution, which carries the oxygen or any type of drug or nutrient that the developers wish to place into the nanoparticle.
Makefield Therapeutics has licensed Intellectual Property covering a novel platform technology from Albert Einstein College of Medicine of Yeshiva University for the generation of powders comprised of hydrogel/glassy matrix (hybrid) nanoparticles that in a first application are delivering controlled and sustained therapeutic levels of gaseous nitric oxide
The company is focused on realizing the potential of RNAi-based therapeutics through the development of a broad-based, state-of-the-art drug discovery platform built upon industry leading expertise in RNA chemistry and oligonucleotide delivery.
MSI's technology for multi-step multi-analyte chemiluminescent assays combines microfluidics, nanotechnology, and optoelectronics designed for both Immunoassay and Nucleic Acid Hybridization based applications.
MicroConstants is a GLP-compliant Contract Research Organization (CRO) dedicated to providing premier quality bioanalytical, drug metabolism, pharmacokinetic, formulation and immunoassay support services to pharmaceutical and biotech companies worldwide.
NABsys is developing its proprietary Hybridization-Assisted Nanopore Sequencing (HANS) platform. This platform combines bleeding edge technology in physics, biochemistry, and computer science to sequence DNA in a way that is projected to be orders of magnitude cheaper and faster than any technology available today.
The company manufactures the Bio-Assembler, a device for culturing cells in three-dimensions by magnetic levitation. The Bio-Assembler combines nanoparticle based Nanoshuttle-PL with designed magnetic fields needed to levitate cells and provide the 3D cell growth environment.
Nanocopoeia is a therapeutic particle engineering company providing nano-enabled particle design, services, and equipment to the pharmaceutical industry. Their patented ElectroNanospray™ (ENS) process is used to produce homogeneous nanoparticles in a unique one-step continuous process. They have the ability to engineer multicomponent particles. ENS is a non-destructive process operating at ambient temperature and pressure. The modular equipment design allows for easy entry at R&D scale moving to pilot and full scale production.
NanoCor intends to use its proprietary Biological Nanoparticle technology platform and a proprietary, patent-protected gene to provide Chronic Heart Failure patients worldwide with an effective, economic, and safe alternative.